Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
9.85
-0.27 (-2.67%)
Sep 25, 2026, 4:00 PM EDT - Market closed
Lyell Immunopharma Employees
Lyell Immunopharma had 161 employees as of December 31, 2025. The number of employees decreased by 139 or -46.33% compared to the previous year.
Employees
161
Change (1Y)
-139
Growth (1Y)
-46.33%
Revenue / Employee
$168
Profits / Employee
-$1,543,335
Market Cap
241.38M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 161 | -139 | -46.33% | 161 | 0 |
| Dec 31, 2024 | 300 | 76 | 33.93% | 300 | 0 |
| Dec 31, 2023 | 224 | -50 | -18.25% | 224 | 0 |
| Dec 31, 2022 | 274 | 55 | 25.11% | 274 | 0 |
| Dec 31, 2021 | 219 | 29 | 15.26% | 219 | 0 |
| Mar 31, 2021 | 190 | - | - | 188 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| ProQR Therapeutics | 187 |
| AC Immune | 122 |
| Zentalis Pharmaceuticals | 106 |
| Keros Therapeutics | 92 |
| Sionna Therapeutics | 59 |
| Pyxis Oncology | 56 |
| Camp4 Therapeutics | 48 |
LYEL News
- 12 days ago - Lyell Immunopharma Transcript: 2026 Global Healthcare Conference - Transcripts
- 13 days ago - Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference - GlobeNewsWire
- 17 days ago - Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer - GlobeNewsWire
- 7 weeks ago - Lyell Immunopharma reports Q2 net loss ($44.8M) vs. ($42.7M) last year - TheFly
- 7 weeks ago - Lyell Immunopharma Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Lyell Immunopharma Earnings release: Q2 2026 - Filings
- 7 weeks ago - Lyell Immunopharma Slides: Company presentation - Filings
- 7 weeks ago - Lyell Immunopharma initiated with a Buy at Stifel - TheFly